[144] BioNTech SE American Depositary Share SEC Filing
BioNTech SE (BNTX) Form 144 notice reports a proposed sale of 500,000 American Depositary Shares through Goldman Sachs & Co. LLC with an approximate aggregate market value of $56,230,000 and an approximate sale date of 09/05/2025. The ADS class shows 237,725,735 shares outstanding. The filing states the 500,000 ADS were originally acquired in a private placement on 01/05/2018 from BioNTech SE and paid in cash. The notice also lists multiple prior sales by AT Impf GmbH during the past three months, including transactions on 06/05/2025 (50,000 ADS), 07/10/2025 (40,000 ADS), and several July 2025 dates down to 4,500 and 500 ADS, each with reported gross proceeds. The filer certifies no undisclosed material adverse information.
Avviso Form 144 di BioNTech SE (BNTX) segnala la proposta di vendita di 500.000 American Depositary Shares tramite Goldman Sachs & Co. LLC per un valore di mercato aggregato approssimativo di $56.230.000, con data di vendita indicativa 09/05/2025. La classe ADS conta 237.725.735 azioni in circolazione. La documentazione dichiara che le 500.000 ADS sono state originariamente acquistate in una offerta privata il 01/05/2018 da BioNTech SE e pagate in contanti. L鈥檃vviso elenca inoltre diverse vendite precedenti effettuate da AT Impf GmbH negli ultimi tre mesi, incluse operazioni del 06/05/2025 (50.000 ADS), del 07/10/2025 (40.000 ADS) e varie date di luglio 2025 con lotti fino a 4.500 e 500 ADS, ciascuna con i proventi lordi riportati. Il dichiarante certifica l鈥檃ssenza di informazioni materiali sfuggite alla comunicazione.
Aviso Form 144 de BioNTech SE (BNTX) informa sobre la propuesta de venta de 500.000 American Depositary Shares a trav茅s de Goldman Sachs & Co. LLC por un valor de mercado agregado aproximado de $56.230.000, con fecha de venta estimada 09/05/2025. La clase ADS muestra 237.725.735 acciones en circulaci贸n. El expediente indica que las 500.000 ADS se adquirieron originalmente en una colocaci贸n privada el 01/05/2018 con BioNTech SE y fueron pagadas en efectivo. El aviso tambi茅n enumera m煤ltiples ventas previas de AT Impf GmbH durante los 煤ltimos tres meses, incluidas transacciones el 06/05/2025 (50.000 ADS), el 07/10/2025 (40.000 ADS) y varias fechas de julio de 2025 con lotes de hasta 4.500 y 500 ADS, cada una con los ingresos brutos reportados. El declarante certifica que no existe informaci贸n material adversa no divulgada.
BioNTech SE (BNTX) Form 144 瓿奠电� Goldman Sachs & Co. LLC毳� 韱淀暣 500,000 American Depositary Shares毳� 毵り皝頃� 鞓堨爼鞚措┌, 齑� 鞁滌灔 臧�旃� 鞎� $56,230,000, 鞓堨儊 毵り皝鞚检潃 2025-09-05搿� 氤搓碃頃╇媹雼�. 頃措嫻 ADS 韥措灅鞀れ潣 氚滍枆 欤检嫕 靾樀鐢 237,725,735欤检瀰雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 鞚� 500,000 ADS电� 鞗愲灅 2018-01-05鞚� 靷 氚滍枆鞙茧 BioNTech SE搿滊秬韯� 順勱笀鞙茧 旆摑霅� 瓴冹澊霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 瓿奠鞐惖鐢 霕愴暅 AT Impf GmbH臧� 歆�雮� 靹� 雼� 霃欖晥 鞐煬 彀 毵る弰頃� 雮挫毄鞚� 雮橃棿霅橃柎 鞛堨溂氅�, 2025-06-05 (50,000 ADS), 2025-07-10 (40,000 ADS) 氚� 2025雲� 7鞗旍潣 鞐煬 雮犾鞐� 瓯胳硱 4,500 氚� 500 ADS 霌� 攴滊氤� 瓯半灅鞕� 鞁犼碃霅� 齑濎垬鞚奠澊 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 鞚胳頃╇媹雼�.
Avis Form 144 de BioNTech SE (BNTX) signale la proposition de vente de 500 000 American Depositary Shares via Goldman Sachs & Co. LLC, pour une valeur de march茅 agr茅g茅e approximative de 56 230 000 $ et une date de vente approximative au 05/09/2025. La cat茅gorie d鈥橝DS compte 237 725 735 actions en circulation. Le d茅p么t indique que les 500 000 ADS ont 茅t茅 initialement acquises lors d鈥檜n placement priv茅 le 05/01/2018 aupr猫s de BioNTech SE et pay茅es en esp猫ces. L鈥檃vis 茅num猫re 茅galement plusieurs ventes ant茅rieures par AT Impf GmbH au cours des trois derniers mois, y compris des op茅rations le 05/06/2025 (50 000 ADS), le 10/07/2025 (40 000 ADS) et plusieurs dates de juillet 2025 jusqu鈥櫭� des lots de 4 500 et 500 ADS, chacune avec les produits bruts d茅clar茅s. Le d茅clarant certifie l鈥檃bsence d鈥檌nformations d茅favorables significatives non divulgu茅es.
Form-144-Mitteilung von BioNTech SE (BNTX) meldet einen geplanten Verkauf von 500.000 American Depositary Shares 眉产别谤 Goldman Sachs & Co. LLC mit einem gesch盲tzten Gesamtmarktwert von $56.230.000 und einem ungef盲hren Verkaufstermin am 05.09.2025. Die ADS-Klasse weist 237.725.735 ausstehende Aktien auf. In der Einreichung hei脽t es, die 500.000 ADS seien urspr眉nglich in einer Privatplatzierung am 05.01.2018 von BioNTech SE erworben und bar bezahlt worden. Die Mitteilung listet au脽erdem mehrere vorherige Verk盲ufe von AT Impf GmbH in den letzten drei Monaten auf, darunter Transaktionen am 05.06.2025 (50.000 ADS), 10.07.2025 (40.000 ADS) und mehrere Termine im Juli 2025 mit Losgr枚脽en bis 4.500 und 500 ADS, jeweils mit gemeldeten Bruttoerl枚sen. Der Einreicher best盲tigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen.
- Securities were acquired in a documented private placement and paid in cash on 01/05/2018
- Filer certifies no undisclosed material adverse information
- Broker for the proposed sale is a major, regulated dealer (Goldman Sachs & Co. LLC)
- Proposed sale is large: 500,000 ADS with aggregate market value of $56,230,000
- Same account (AT Impf GmbH) executed multiple ADS sales in the prior three months, indicating recent disposal activity
Insights
TL;DR: A sizeable block of 500,000 ADS (about $56.2M) is being offered by a holder with recent sales activity, which may increase supply of ADS in the market.
The filing documents a proposed sale of 500,000 ADS via Goldman Sachs with an aggregate market value of $56,230,000 and an intended sale date of 09/05/2025. The securities were acquired in a private placement on 01/05/2018 and paid in cash. The same account (AT Impf GmbH) has executed multiple ADS sales across June and July 2025, with transactions ranging from 500 to 50,000 ADS and disclosed gross proceeds for each trade. For investors, the combination of a large single proposed sale and recent patterned disposals by the same seller is a liquidity and supply signal; the filing itself contains no statements about use of proceeds or insider plans beyond the rule 144 representations.
TL;DR: This is a routine Rule 144 notice documenting an eligible sale; disclosure appears consistent with procedural requirements.
The Form 144 provides the required disclosure items: identity of broker, number of ADS to be sold, acquisition history showing an arm's-length private placement acquisition, and prior sales in the past three months. The signer affirms absence of undisclosed material adverse information. There are no governance or dilution actions disclosed beyond the sale itself; the filing does not indicate any change in ownership structure or related-party transactions other than the recorded sales activity.
Avviso Form 144 di BioNTech SE (BNTX) segnala la proposta di vendita di 500.000 American Depositary Shares tramite Goldman Sachs & Co. LLC per un valore di mercato aggregato approssimativo di $56.230.000, con data di vendita indicativa 09/05/2025. La classe ADS conta 237.725.735 azioni in circolazione. La documentazione dichiara che le 500.000 ADS sono state originariamente acquistate in una offerta privata il 01/05/2018 da BioNTech SE e pagate in contanti. L鈥檃vviso elenca inoltre diverse vendite precedenti effettuate da AT Impf GmbH negli ultimi tre mesi, incluse operazioni del 06/05/2025 (50.000 ADS), del 07/10/2025 (40.000 ADS) e varie date di luglio 2025 con lotti fino a 4.500 e 500 ADS, ciascuna con i proventi lordi riportati. Il dichiarante certifica l鈥檃ssenza di informazioni materiali sfuggite alla comunicazione.
Aviso Form 144 de BioNTech SE (BNTX) informa sobre la propuesta de venta de 500.000 American Depositary Shares a trav茅s de Goldman Sachs & Co. LLC por un valor de mercado agregado aproximado de $56.230.000, con fecha de venta estimada 09/05/2025. La clase ADS muestra 237.725.735 acciones en circulaci贸n. El expediente indica que las 500.000 ADS se adquirieron originalmente en una colocaci贸n privada el 01/05/2018 con BioNTech SE y fueron pagadas en efectivo. El aviso tambi茅n enumera m煤ltiples ventas previas de AT Impf GmbH durante los 煤ltimos tres meses, incluidas transacciones el 06/05/2025 (50.000 ADS), el 07/10/2025 (40.000 ADS) y varias fechas de julio de 2025 con lotes de hasta 4.500 y 500 ADS, cada una con los ingresos brutos reportados. El declarante certifica que no existe informaci贸n material adversa no divulgada.
BioNTech SE (BNTX) Form 144 瓿奠电� Goldman Sachs & Co. LLC毳� 韱淀暣 500,000 American Depositary Shares毳� 毵り皝頃� 鞓堨爼鞚措┌, 齑� 鞁滌灔 臧�旃� 鞎� $56,230,000, 鞓堨儊 毵り皝鞚检潃 2025-09-05搿� 氤搓碃頃╇媹雼�. 頃措嫻 ADS 韥措灅鞀れ潣 氚滍枆 欤检嫕 靾樀鐢 237,725,735欤检瀰雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 鞚� 500,000 ADS电� 鞗愲灅 2018-01-05鞚� 靷 氚滍枆鞙茧 BioNTech SE搿滊秬韯� 順勱笀鞙茧 旆摑霅� 瓴冹澊霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 瓿奠鞐惖鐢 霕愴暅 AT Impf GmbH臧� 歆�雮� 靹� 雼� 霃欖晥 鞐煬 彀 毵る弰頃� 雮挫毄鞚� 雮橃棿霅橃柎 鞛堨溂氅�, 2025-06-05 (50,000 ADS), 2025-07-10 (40,000 ADS) 氚� 2025雲� 7鞗旍潣 鞐煬 雮犾鞐� 瓯胳硱 4,500 氚� 500 ADS 霌� 攴滊氤� 瓯半灅鞕� 鞁犼碃霅� 齑濎垬鞚奠澊 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 鞚胳頃╇媹雼�.
Avis Form 144 de BioNTech SE (BNTX) signale la proposition de vente de 500 000 American Depositary Shares via Goldman Sachs & Co. LLC, pour une valeur de march茅 agr茅g茅e approximative de 56 230 000 $ et une date de vente approximative au 05/09/2025. La cat茅gorie d鈥橝DS compte 237 725 735 actions en circulation. Le d茅p么t indique que les 500 000 ADS ont 茅t茅 initialement acquises lors d鈥檜n placement priv茅 le 05/01/2018 aupr猫s de BioNTech SE et pay茅es en esp猫ces. L鈥檃vis 茅num猫re 茅galement plusieurs ventes ant茅rieures par AT Impf GmbH au cours des trois derniers mois, y compris des op茅rations le 05/06/2025 (50 000 ADS), le 10/07/2025 (40 000 ADS) et plusieurs dates de juillet 2025 jusqu鈥櫭� des lots de 4 500 et 500 ADS, chacune avec les produits bruts d茅clar茅s. Le d茅clarant certifie l鈥檃bsence d鈥檌nformations d茅favorables significatives non divulgu茅es.
Form-144-Mitteilung von BioNTech SE (BNTX) meldet einen geplanten Verkauf von 500.000 American Depositary Shares 眉产别谤 Goldman Sachs & Co. LLC mit einem gesch盲tzten Gesamtmarktwert von $56.230.000 und einem ungef盲hren Verkaufstermin am 05.09.2025. Die ADS-Klasse weist 237.725.735 ausstehende Aktien auf. In der Einreichung hei脽t es, die 500.000 ADS seien urspr眉nglich in einer Privatplatzierung am 05.01.2018 von BioNTech SE erworben und bar bezahlt worden. Die Mitteilung listet au脽erdem mehrere vorherige Verk盲ufe von AT Impf GmbH in den letzten drei Monaten auf, darunter Transaktionen am 05.06.2025 (50.000 ADS), 10.07.2025 (40.000 ADS) und mehrere Termine im Juli 2025 mit Losgr枚脽en bis 4.500 und 500 ADS, jeweils mit gemeldeten Bruttoerl枚sen. Der Einreicher best盲tigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen.
FAQ
What does the Form 144 for BioNTech (BNTX) disclose?
Who originally acquired the 500,000 ADS and when?
Has the selling account traded BioNTech ADS recently?
Who is acting as broker for the proposed sale?
How many shares outstanding are reported for the ADS class?
